»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
¾È°ú Ä¡·áÁ¦ ½ÃÀåÀº 2024-2029³â¿¡ 253¾ï ´Þ·¯ Áõ°¡Çϰí, ¿¹Ãø ±â°£Áß CAGR 7.4%ÀÇ ¼ºÀåÀÌ ¿¹ÃøµË´Ï´Ù.
¼¼°èÀÇ ¾È°ú¿ë Ä¡·áÁ¦ ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇßÀ¸¸ç, ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, µ¿Çâ, ¼ºÀå ÃËÁø¿äÀÎ, °úÁ¦, ¾à 25°³ º¥´õ¿¡ ´ëÇÑ º¥´õ ºÐ¼® µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
ÇöÀçÀÇ ½ÃÀå ½Ã³ª¸®¿À, Ãֽе¿Çâ ¹× ¼ºÀå¿äÀÎ, ½ÃÀå ȯ°æ Àü¹Ý¿¡ ´ëÇÑ ÃֽŠºÐ¼®À» Á¦°øÇÕ´Ï´Ù. ¾ÈÁúȯ À¯º´·ü Áõ°¡, ½Å±Ô Ä¡·áÁ¦ ½ÂÀΰú °·ÂÇÑ ÀǾàǰ ÆÄÀÌÇÁ¶óÀÎ, Ç×VEGF ¾ïÁ¦Á¦ÀÇ °·ÂÇÑ ½ÃÀå ÁøÀÔ¿¡ ÀÇÇØ ½ÃÀåÀÌ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù.
½ÃÀå ¹üÀ§
±âÁØ ¿¬µµ
2025³â
Á¾·á ¿¬µµ
2029³â
¿¹Ãø ±â°£
2025-2029³â
¼ºÀå ¸ð¸àÅÒ
°¡¼Ó
Àü³â´ëºñ
6.7%
CAGR
7.4%
Áõ°¡¾×
253¾ï ´Þ·¯
º» Á¶»ç´Â ¾÷°è ÁÖ¿ä Âü¿©ÀÚµéÀÇ ÀǰßÀ» Æ÷ÇÔÇÏ¿© 1Â÷ Á¤º¸¿Í 2Â÷ Á¤º¸¸¦ °´°üÀûÀ¸·Î Á¶ÇÕÇÏ¿© ½Ç½ÃµÇ¾ú½À´Ï´Ù. ÀÌ º¸°í¼¿¡´Â ÁÖ¿ä ±â¾÷ ºÐ¼®°ú ÇÔ²² Á¾ÇÕÀûÀÎ ½ÃÀå ±Ô¸ð µ¥ÀÌÅÍ, Áö¿ª ºÐ¼®¿¡ µû¸¥ ºÎ¹®, °ø±Þ¾÷ü ÇöȲÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. º¸°í¼¿¡´Â °ú°Å µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅͰ¡ ÀÖ½À´Ï´Ù.
º» Á¶»ç¿¡¼´Â ÇâÈÄ ¼ö³â°£ ¾È°ú Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß Çϳª·Î »õ·Î¿î ¾à¹° Àü´Þ ½Ã½ºÅÛÀÇ °³¹ßÀ» ²Å¾Ò½À´Ï´Ù. ¶ÇÇÑ, Àü·«Àû Á¦ÈÞ Áõ°¡¿Í À¯ÀüÀÚ Ä¡·á Á¦Ç°¿¡ ´ëÇÑ Á¶»ç Áõ°¡´Â ½ÃÀåÀÇ Å« ¼ö¿ä·Î À̾îÁú °ÍÀÔ´Ï´Ù.
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå Technavio ºÐ¼®
°¡°Ý, ¼ö¸íÁÖ±â, °í°´ ±¸ÀÔ ¹Ù½ºÄÏ, äÅà ºñÀ², ±¸ÀÔ ±âÁØ ºÐ¼®
ÀÎDzÀÇ Á߿伺°ú Â÷º°È ¿äÀÎ
È¥¶õ ¿äÀÎ
¼ºÀå ÃËÁø¿äÀΰú °úÁ¦ÀÇ ¿µÇâ
Á¦3Àå ½ÃÀå ±¸µµ
½ÃÀå »ýŰè
½ÃÀå Æ¯Â¡
¹ë·ùüÀÎ ºÐ¼®
Á¦4Àå ½ÃÀå ±Ô¸ð
½ÃÀåÀÇ Á¤ÀÇ
½ÃÀå ºÎ¹® ºÐ¼®
½ÃÀå ±Ô¸ð(2024³â)
½ÃÀå Àü¸Á(2024-2029³â)
Á¦5Àå ½ÃÀå ±Ô¸ð ½ÇÀû
¼¼°èÀÇ ¾È°ú Ä¡·áÁ¦ ½ÃÀå(2019-2023³â)
À¯Çüº° ºÐ¼®(2019-2023³â)
Á¦Ç°º° ºÐ¼®(2019-2023³â)
¾àÁ¦ Ŭ·¡½ºº° ºÐ¼®(2019-2023³â)
Áö¿ªº° ºÐ¼®(2019-2023³â)
±¹°¡º° ºÐ¼®(2019-2023³â)
Á¦6Àå Á¤¼º ºÐ¼®
AIÀÇ ¿µÇâ : ¼¼°èÀÇ ¾È°ú Ä¡·áÁ¦ ½ÃÀå
Á¦7Àå Five Forces ºÐ¼®
Five Forces ¿ä¾à
¹ÙÀ̾îÀÇ ±³¼··Â
°ø±Þ ±â¾÷ÀÇ ±³¼··Â
½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
´ëüǰÀÇ À§Çù
°æÀï À§Çù
½ÃÀå ÇöȲ
Á¦8Àå ½ÃÀå ¼¼ºÐÈ : À¯Çüº°
½ÃÀå ºÎ¹®
ºñ±³ : À¯Çüº°
󹿾à : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
OTC ÀǾàǰ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
½ÃÀå ±âȸ : À¯Çüº°
Á¦9Àå ½ÃÀå ¼¼ºÐÈ : Á¦Ç°º°
½ÃÀå ºÎ¹®
ºñ±³ : Á¦Ç°º°
¸Á¸·Áúȯ Ä¡·áÁ¦ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
³ì³»Àå Ä¡·áÁ¦ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
¾È±¸°ÇÁ¶Áõ Ä¡·áÁ¦ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
´« °¨¿°Áõ ¹× ¿°Áõ Ä¡·áÁ¦ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
±âŸ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
½ÃÀå ±âȸ : Á¦Ç°º°
Á¦10Àå ½ÃÀå ¼¼ºÐÈ : ¾àÁ¦ Ŭ·¡½ºº°
½ÃÀå ºÎ¹®
ºñ±³ : ¾àÁ¦ Ŭ·¡½ºº°
Ç×VEGF¾à : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
Ç׿°ÁõÁ¦ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
³ì³»Àå Ä¡·áÁ¦ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
Ç×°¨¿°Áõ¾à : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
±âŸ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
½ÃÀå ±âȸ : ¾àÁ¦ Ŭ·¡½ºº°
Á¦11Àå °í°´ »óȲ
Á¦12Àå Áö¿ªº° »óȲ
Áö¿ªº° ¼¼ºÐÈ
Áö¿ªº° ºñ±³
ºÏ¹Ì : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
À¯·´ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
¾Æ½Ã¾Æ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
¼¼°è ±âŸ Áö¿ª : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
¹Ì±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
ij³ª´Ù : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
µ¶ÀÏ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
¿µ±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
ÀϺ» : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
ÇÁ¶û½º : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
Áß±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
Àεµ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
ÀÌÅ»¸®¾Æ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
Çѱ¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
½ÃÀå ±âȸ : Áö¿ª »óȲº°
Á¦13Àå ¼ºÀå ÃËÁø¿äÀÎ, °úÁ¦, ±âȸ ¹× ¼ºÀå ¾ïÁ¦¿äÀÎ
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
¼ºÀå ÃËÁø¿äÀΰú °úÁ¦ÀÇ ¿µÇâ
½ÃÀå ±âȸ¿Í ¼ºÀå ¾ïÁ¦¿äÀÎ
Á¦14Àå °æÀï ±¸µµ
°³¿ä
°æÀï ±¸µµ
ÆÄ±«Àû Çõ½Å »óȲ
¾÷°è ¸®½ºÅ©
Á¦15Àå °æÀï ºÐ¼®
±â¾÷ °³¿ä
±â¾÷ ¼øÀ§ Áö¼ö
±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Å´×
AbbVie Inc.
Aldeyra Therapeutics Inc
Apellis Pharmaceuticals Inc.
Bausch Health Companies Inc.
Bayer AG
F. Hoffmann La Roche Ltd.
Novartis AG
Ocular Therapeutix Inc
Otsuka Pharmaceutical Co Ltd.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Santen Pharmaceutical Co. Ltd.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Visufarma
Á¦16Àå ºÎ·Ï
LSH
The ophthalmology therapeutics market is forecasted to grow by USD 25.3 bn during 2024-2029, accelerating at a CAGR of 7.4% during the forecast period. The report on the ophthalmology therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increase in prevalence of eye diseases, approval of novel therapeutics and strong drug pipeline, and strong uptake of anti-vegf inhibitors.
Market Scope
Base Year 2025
End Year 2029
Series Year 2025-2029
Growth Momentum Accelerate
YOY 2025 6.7%
CAGR 7.4%
Incremental Value $25.3 bn
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
Technavio's ophthalmology therapeutics market is segmented as below:
By Type
Prescription drugs
OTC drugs
By Product
Retinal disorder therapeutics
Glaucoma therapeutics
Dry eye disease therapeutics
Eye infections and inflammation therapeutics
Others
By Drug Class
Anti-VEGF
Anti-inflammatory
Anti-glaucoma
Anti-infectives
Others
By Geographical Landscape
North America
Europe
Asia
Rest of World (ROW)
This study identifies the development of novel drug delivery systems as one of the prime reasons driving the ophthalmology therapeutics market growth during the next few years. Also, increase in strategic alliances and increasing research on gene therapy products will lead to sizable demand in the market.
The report on the ophthalmology therapeutics market covers the following areas:
Ophthalmology Therapeutics Market sizing
Ophthalmology Therapeutics Market forecast
Ophthalmology Therapeutics Market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading ophthalmology therapeutics market vendors that include AbbVie Inc., Alcon Inc., Aldeyra Therapeutics Inc, Alembic Pharmaceuticals Ltd., Apellis Pharmaceuticals Inc., Bausch Health Companies Inc., Bayer AG, Boehringer Ingelheim International GmbH, F. Hoffmann La Roche Ltd., Johnson and Johnson Services Inc., MeiraGTx Holdings Plc., Novartis AG, Ocular Therapeutix Inc, Otsuka Pharmaceutical Co Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Visufarma. Also, the ophthalmology therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
1.1 Market overview
Executive Summary - Chart on Market Overview
Executive Summary - Data Table on Market Overview
Executive Summary - Chart on Global Market Characteristics
Executive Summary - Chart on Market By Geographical Landscape
Executive Summary - Chart on Market Segmentation by Type
Executive Summary - Chart on Market Segmentation by Product
Executive Summary - Chart on Market Segmentation by Drug Class
Executive Summary - Chart on Incremental Growth
Executive Summary - Data Table on Incremental Growth
Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
2.2 Criticality of inputs and Factors of differentiation
Overview on criticality of inputs and factors of differentiation
2.3 Factors of disruption
Overview on factors of disruption
2.4 Impact of drivers and challenges
Impact of drivers and challenges in 2024 and 2029
3 Market Landscape
3.1 Market ecosystem
Parent Market
Data Table on - Parent Market
3.2 Market characteristics
Market characteristics analysis
3.3 Value chain analysis
4 Market Sizing
4.1 Market definition
Offerings of companies included in the market definition
4.2 Market segment analysis
4.3 Market size 2024
4.4 Market outlook: Forecast for 2024-2029
Chart on Global - Market size and forecast 2024-2029 ($ billion)
Data Table on Global - Market size and forecast 2024-2029 ($ billion)
Chart on Global Market: Year-over-year growth 2024-2029 (%)
Data Table on Global Market: Year-over-year growth 2024-2029 (%)
5 Historic Market Size
5.1 Global Ophthalmology Therapeutics Market 2019 - 2023
Historic Market Size - Data Table on Global Ophthalmology Therapeutics Market 2019 - 2023 ($ billion)
5.2 Type segment analysis 2019 - 2023
Historic Market Size - Type Segment 2019 - 2023 ($ billion)
5.3 Product segment analysis 2019 - 2023
Historic Market Size - Product Segment 2019 - 2023 ($ billion)
5.4 Drug Class segment analysis 2019 - 2023
Historic Market Size - Drug Class Segment 2019 - 2023 ($ billion)
5.5 Geography segment analysis 2019 - 2023
Historic Market Size - Geography Segment 2019 - 2023 ($ billion)
5.6 Country segment analysis 2019 - 2023
Historic Market Size - Country Segment 2019 - 2023 ($ billion)
6 Qualitative Analysis
6.1 The AI impact on Global Ophthalmology Therapeutics Market
7 Five Forces Analysis
7.1 Five forces summary
Five forces analysis - Comparison between 2024 and 2029
7.2 Bargaining power of buyers
Bargaining power of buyers - Impact of key factors 2024 and 2029
7.3 Bargaining power of suppliers
Bargaining power of suppliers - Impact of key factors in 2024 and 2029
7.4 Threat of new entrants
Threat of new entrants - Impact of key factors in 2024 and 2029
7.5 Threat of substitutes
Threat of substitutes - Impact of key factors in 2024 and 2029
7.6 Threat of rivalry
Threat of rivalry - Impact of key factors in 2024 and 2029
7.7 Market condition
Chart on Market condition - Five forces 2024 and 2029
8 Market Segmentation by Type
8.1 Market segments
Chart on Type - Market share 2024-2029 (%)
Data Table on Type - Market share 2024-2029 (%)
8.2 Comparison by Type
Chart on Comparison by Type
Data Table on Comparison by Type
8.3 Prescription drugs - Market size and forecast 2024-2029
Chart on Prescription drugs - Market size and forecast 2024-2029 ($ billion)
Data Table on Prescription drugs - Market size and forecast 2024-2029 ($ billion)
Chart on Prescription drugs - Year-over-year growth 2024-2029 (%)
Data Table on Prescription drugs - Year-over-year growth 2024-2029 (%)
8.4 OTC drugs - Market size and forecast 2024-2029
Chart on OTC drugs - Market size and forecast 2024-2029 ($ billion)
Data Table on OTC drugs - Market size and forecast 2024-2029 ($ billion)
Chart on OTC drugs - Year-over-year growth 2024-2029 (%)
Data Table on OTC drugs - Year-over-year growth 2024-2029 (%)
8.5 Market opportunity by Type
Market opportunity by Type ($ billion)
Data Table on Market opportunity by Type ($ billion)
9 Market Segmentation by Product
9.1 Market segments
Chart on Product - Market share 2024-2029 (%)
Data Table on Product - Market share 2024-2029 (%)
9.2 Comparison by Product
Chart on Comparison by Product
Data Table on Comparison by Product
9.3 Retinal disorder therapeutics - Market size and forecast 2024-2029
Chart on Retinal disorder therapeutics - Market size and forecast 2024-2029 ($ billion)
Data Table on Retinal disorder therapeutics - Market size and forecast 2024-2029 ($ billion)
Chart on Retinal disorder therapeutics - Year-over-year growth 2024-2029 (%)
Data Table on Retinal disorder therapeutics - Year-over-year growth 2024-2029 (%)
9.4 Glaucoma therapeutics - Market size and forecast 2024-2029
Chart on Glaucoma therapeutics - Market size and forecast 2024-2029 ($ billion)
Data Table on Glaucoma therapeutics - Market size and forecast 2024-2029 ($ billion)
Chart on Glaucoma therapeutics - Year-over-year growth 2024-2029 (%)
Data Table on Glaucoma therapeutics - Year-over-year growth 2024-2029 (%)
9.5 Dry eye disease therapeutics - Market size and forecast 2024-2029
Chart on Dry eye disease therapeutics - Market size and forecast 2024-2029 ($ billion)
Data Table on Dry eye disease therapeutics - Market size and forecast 2024-2029 ($ billion)
Chart on Dry eye disease therapeutics - Year-over-year growth 2024-2029 (%)
Data Table on Dry eye disease therapeutics - Year-over-year growth 2024-2029 (%)
9.6 Eye infections and inflammation therapeutics - Market size and forecast 2024-2029
Chart on Eye infections and inflammation therapeutics - Market size and forecast 2024-2029 ($ billion)
Data Table on Eye infections and inflammation therapeutics - Market size and forecast 2024-2029 ($ billion)
Chart on Eye infections and inflammation therapeutics - Year-over-year growth 2024-2029 (%)
Data Table on Eye infections and inflammation therapeutics - Year-over-year growth 2024-2029 (%)
9.7 Others - Market size and forecast 2024-2029
Chart on Others - Market size and forecast 2024-2029 ($ billion)
Data Table on Others - Market size and forecast 2024-2029 ($ billion)
Chart on Others - Year-over-year growth 2024-2029 (%)
Data Table on Others - Year-over-year growth 2024-2029 (%)
9.8 Market opportunity by Product
Market opportunity by Product ($ billion)
Data Table on Market opportunity by Product ($ billion)
10 Market Segmentation by Drug Class
10.1 Market segments
Chart on Drug Class - Market share 2024-2029 (%)
Data Table on Drug Class - Market share 2024-2029 (%)
10.2 Comparison by Drug Class
Chart on Comparison by Drug Class
Data Table on Comparison by Drug Class
10.3 Anti-VEGF - Market size and forecast 2024-2029
Chart on Anti-VEGF - Market size and forecast 2024-2029 ($ billion)
Data Table on Anti-VEGF - Market size and forecast 2024-2029 ($ billion)
Chart on Anti-VEGF - Year-over-year growth 2024-2029 (%)
Data Table on Anti-VEGF - Year-over-year growth 2024-2029 (%)
10.4 Anti-inflammatory - Market size and forecast 2024-2029
Chart on Anti-inflammatory - Market size and forecast 2024-2029 ($ billion)
Data Table on Anti-inflammatory - Market size and forecast 2024-2029 ($ billion)
Chart on Anti-inflammatory - Year-over-year growth 2024-2029 (%)
Data Table on Anti-inflammatory - Year-over-year growth 2024-2029 (%)
10.5 Anti-glaucoma - Market size and forecast 2024-2029
Chart on Anti-glaucoma - Market size and forecast 2024-2029 ($ billion)
Data Table on Anti-glaucoma - Market size and forecast 2024-2029 ($ billion)
Chart on Anti-glaucoma - Year-over-year growth 2024-2029 (%)
Data Table on Anti-glaucoma - Year-over-year growth 2024-2029 (%)
10.6 Anti-infectives - Market size and forecast 2024-2029
Chart on Anti-infectives - Market size and forecast 2024-2029 ($ billion)
Data Table on Anti-infectives - Market size and forecast 2024-2029 ($ billion)
Chart on Anti-infectives - Year-over-year growth 2024-2029 (%)
Data Table on Anti-infectives - Year-over-year growth 2024-2029 (%)
10.7 Others - Market size and forecast 2024-2029
Chart on Others - Market size and forecast 2024-2029 ($ billion)
Data Table on Others - Market size and forecast 2024-2029 ($ billion)
Chart on Others - Year-over-year growth 2024-2029 (%)
Data Table on Others - Year-over-year growth 2024-2029 (%)
10.8 Market opportunity by Drug Class
Market opportunity by Drug Class ($ billion)
Data Table on Market opportunity by Drug Class ($ billion)
11 Customer Landscape
11.1 Customer landscape overview
Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
12.1 Geographic segmentation
Chart on Market share By Geographical Landscape 2024-2029 (%)
Data Table on Market share By Geographical Landscape 2024-2029 (%)
12.2 Geographic comparison
Chart on Geographic comparison
Data Table on Geographic comparison
12.3 North America - Market size and forecast 2024-2029
Chart on North America - Market size and forecast 2024-2029 ($ billion)
Data Table on North America - Market size and forecast 2024-2029 ($ billion)
Chart on North America - Year-over-year growth 2024-2029 (%)
Data Table on North America - Year-over-year growth 2024-2029 (%)
12.4 Europe - Market size and forecast 2024-2029
Chart on Europe - Market size and forecast 2024-2029 ($ billion)
Data Table on Europe - Market size and forecast 2024-2029 ($ billion)
Chart on Europe - Year-over-year growth 2024-2029 (%)
Data Table on Europe - Year-over-year growth 2024-2029 (%)
12.5 Asia - Market size and forecast 2024-2029
Chart on Asia - Market size and forecast 2024-2029 ($ billion)
Data Table on Asia - Market size and forecast 2024-2029 ($ billion)
Chart on Asia - Year-over-year growth 2024-2029 (%)
Data Table on Asia - Year-over-year growth 2024-2029 (%)
12.6 Rest of World (ROW) - Market size and forecast 2024-2029
Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ billion)
Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ billion)
Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
12.7 US - Market size and forecast 2024-2029
Chart on US - Market size and forecast 2024-2029 ($ billion)
Data Table on US - Market size and forecast 2024-2029 ($ billion)
Chart on US - Year-over-year growth 2024-2029 (%)
Data Table on US - Year-over-year growth 2024-2029 (%)
12.8 Canada - Market size and forecast 2024-2029
Chart on Canada - Market size and forecast 2024-2029 ($ billion)
Data Table on Canada - Market size and forecast 2024-2029 ($ billion)
Chart on Canada - Year-over-year growth 2024-2029 (%)
Data Table on Canada - Year-over-year growth 2024-2029 (%)
12.9 Germany - Market size and forecast 2024-2029
Chart on Germany - Market size and forecast 2024-2029 ($ billion)
Data Table on Germany - Market size and forecast 2024-2029 ($ billion)
Chart on Germany - Year-over-year growth 2024-2029 (%)
Data Table on Germany - Year-over-year growth 2024-2029 (%)
12.10 UK - Market size and forecast 2024-2029
Chart on UK - Market size and forecast 2024-2029 ($ billion)
Data Table on UK - Market size and forecast 2024-2029 ($ billion)
Chart on UK - Year-over-year growth 2024-2029 (%)
Data Table on UK - Year-over-year growth 2024-2029 (%)
12.11 Japan - Market size and forecast 2024-2029
Chart on Japan - Market size and forecast 2024-2029 ($ billion)
Data Table on Japan - Market size and forecast 2024-2029 ($ billion)
Chart on Japan - Year-over-year growth 2024-2029 (%)
Data Table on Japan - Year-over-year growth 2024-2029 (%)
12.12 France - Market size and forecast 2024-2029
Chart on France - Market size and forecast 2024-2029 ($ billion)
Data Table on France - Market size and forecast 2024-2029 ($ billion)
Chart on France - Year-over-year growth 2024-2029 (%)
Data Table on France - Year-over-year growth 2024-2029 (%)
12.13 China - Market size and forecast 2024-2029
Chart on China - Market size and forecast 2024-2029 ($ billion)
Data Table on China - Market size and forecast 2024-2029 ($ billion)
Chart on China - Year-over-year growth 2024-2029 (%)
Data Table on China - Year-over-year growth 2024-2029 (%)
12.14 India - Market size and forecast 2024-2029
Chart on India - Market size and forecast 2024-2029 ($ billion)
Data Table on India - Market size and forecast 2024-2029 ($ billion)
Chart on India - Year-over-year growth 2024-2029 (%)
Data Table on India - Year-over-year growth 2024-2029 (%)
12.15 Italy - Market size and forecast 2024-2029
Chart on Italy - Market size and forecast 2024-2029 ($ billion)
Data Table on Italy - Market size and forecast 2024-2029 ($ billion)
Chart on Italy - Year-over-year growth 2024-2029 (%)
Data Table on Italy - Year-over-year growth 2024-2029 (%)
12.16 South Korea - Market size and forecast 2024-2029
Chart on South Korea - Market size and forecast 2024-2029 ($ billion)
Data Table on South Korea - Market size and forecast 2024-2029 ($ billion)
Chart on South Korea - Year-over-year growth 2024-2029 (%)
Data Table on South Korea - Year-over-year growth 2024-2029 (%)
12.17 Market opportunity By Geographical Landscape
Market opportunity By Geographical Landscape ($ billion)
Data Tables on Market opportunity By Geographical Landscape ($ billion)
13 Drivers, Challenges, and Opportunity/Restraints
13.1 Market drivers
13.2 Market challenges
13.3 Impact of drivers and challenges
Impact of drivers and challenges in 2024 and 2029
13.4 Market opportunities/restraints
14 Competitive Landscape
14.1 Overview
14.2 Competitive Landscape
Overview on criticality of inputs and factors of differentiation
14.3 Landscape disruption
Overview on factors of disruption
14.4 Industry risks
Impact of key risks on business
15 Competitive Analysis
15.1 Companies profiled
15.2 Company ranking index
15.3 Market positioning of companies
Matrix on companies position and classification
15.4 AbbVie Inc.
AbbVie Inc. - Overview
AbbVie Inc. - Product / Service
AbbVie Inc. - Key news
AbbVie Inc. - Key offerings
SWOT
15.5 Aldeyra Therapeutics Inc
Aldeyra Therapeutics Inc - Overview
Aldeyra Therapeutics Inc - Product / Service
Aldeyra Therapeutics Inc - Key offerings
SWOT
15.6 Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc. - Overview
Apellis Pharmaceuticals Inc. - Product / Service
Apellis Pharmaceuticals Inc. - Key offerings
SWOT
15.7 Bausch Health Companies Inc.
Bausch Health Companies Inc. - Overview
Bausch Health Companies Inc. - Business segments
Bausch Health Companies Inc. - Key news
Bausch Health Companies Inc. - Key offerings
Bausch Health Companies Inc. - Segment focus
SWOT
15.8 Bayer AG
Bayer AG - Overview
Bayer AG - Business segments
Bayer AG - Key news
Bayer AG - Key offerings
Bayer AG - Segment focus
SWOT
15.9 F. Hoffmann La Roche Ltd.
F. Hoffmann La Roche Ltd. - Overview
F. Hoffmann La Roche Ltd. - Business segments
F. Hoffmann La Roche Ltd. - Key news
F. Hoffmann La Roche Ltd. - Key offerings
F. Hoffmann La Roche Ltd. - Segment focus
SWOT
15.10 Novartis AG
Novartis AG - Overview
Novartis AG - Business segments
Novartis AG - Key news
Novartis AG - Key offerings
Novartis AG - Segment focus
SWOT
15.11 Ocular Therapeutix Inc
Ocular Therapeutix Inc - Overview
Ocular Therapeutix Inc - Product / Service
Ocular Therapeutix Inc - Key offerings
SWOT
15.12 Otsuka Pharmaceutical Co Ltd.
Otsuka Pharmaceutical Co Ltd. - Overview
Otsuka Pharmaceutical Co Ltd. - Product / Service
Otsuka Pharmaceutical Co Ltd. - Key offerings
SWOT
15.13 Pfizer Inc.
Pfizer Inc. - Overview
Pfizer Inc. - Product / Service
Pfizer Inc. - Key news
Pfizer Inc. - Key offerings
SWOT
15.14 Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc. - Overview
Regeneron Pharmaceuticals Inc. - Product / Service
Regeneron Pharmaceuticals Inc. - Key offerings
SWOT
15.15 Santen Pharmaceutical Co. Ltd.
Santen Pharmaceutical Co. Ltd. - Overview
Santen Pharmaceutical Co. Ltd. - Product / Service
Santen Pharmaceutical Co. Ltd. - Key offerings
SWOT
15.16 Sun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd. - Overview
Sun Pharmaceutical Industries Ltd. - Product / Service
Sun Pharmaceutical Industries Ltd. - Key news
Sun Pharmaceutical Industries Ltd. - Key offerings
SWOT
15.17 Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. - Overview
Teva Pharmaceutical Industries Ltd. - Business segments
Teva Pharmaceutical Industries Ltd. - Key news
Teva Pharmaceutical Industries Ltd. - Key offerings
Teva Pharmaceutical Industries Ltd. - Segment focus
SWOT
15.18 Visufarma
Visufarma - Overview
Visufarma - Product / Service
Visufarma - Key offerings
SWOT
16 Appendix
16.1 Scope of the report
16.2 Inclusions and exclusions checklist
Inclusions checklist
Exclusions checklist
16.3 Currency conversion rates for US$
Currency conversion rates for US$
16.4 Research methodology
16.5 Data procurement
16.6 Data validation
16.7 Validation techniques employed for market sizing
Validation techniques employed for market sizing
16.8 Data synthesis
16.9 360 degree market analysis
360 degree market analysis
16.10 List of abbreviations